A novel mixed living high training low intervention and the hematological module of the athlete biological passport.


Journal

Drug testing and analysis
ISSN: 1942-7611
Titre abrégé: Drug Test Anal
Pays: England
ID NLM: 101483449

Informations de publication

Date de publication:
Mar 2020
Historique:
received: 09 07 2019
revised: 15 09 2019
accepted: 22 10 2019
pubmed: 1 1 2020
medline: 18 11 2020
entrez: 1 1 2020
Statut: ppublish

Résumé

Exposure to either natural or simulated hypoxia induces hematological adaptations that may affect the parameters of the Athlete Biological Passport (ABP). The aim of the present study was to examine the effect of a novel, mixed hypoxic dose protocol on the likelihood of producing an atypical ABP finding. Ten well-trained middle-distance runners participated in a "live high, train low and high" (LHTLH) altitude training camp for 14 days. The participants spent ˜6 hr.d-1 at 3000-5400 m during waking hours and ˜10 h.d-1 overnight at 2400-3000 m simulated altitude. Venous blood samples were collected before (B0), and after 1 (D1), 4 (D4), 7 (D7), and 14 (D14) days of hypoxic exposure, and again 14 days post exposure (P14). Samples were analyzed for key parameters of the ABP including reticulocyte percentage (Ret%), hemoglobin concentration ([Hb]), and the OFF-score. The ABP adaptive model was administered at a specificity of 99% to test for atypical findings. We found significant changes in [Hb] and Ret% during the hypoxic intervention. Consequently, this led to ABP threshold deviations at 99% specificity in three participants. Only one of these was flagged as an "atypical passport finding" (ATPF) due to deviation of the OFF-score. When this sample was evaluated by ABP experts it was considered "normal". In conclusion, it is highly unlikely that the present hypoxic exposure protocol would have led to a citation for a doping violation according to WADA guidelines.

Identifiants

pubmed: 31889433
doi: 10.1002/dta.2723
doi:

Substances chimiques

Hemoglobins 0

Types de publication

Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

323-330

Subventions

Organisme : Anti-Doping Laboratory Qatar
Organisme : Aspire Zone Foundation

Informations de copyright

© 2019 John Wiley & Sons, Ltd.

Références

Knaupp W, Khilnani S, Sherwood J, Scharf S, Steinberg H. Erythropoietin response to acute normobaric hypoxia in humans. J Appl Physiol. 1992;73(3):837-840.
Millet GP, Roels B, Schmitt L, Woorons X, Richalet JP. Combining hypoxic methods for peak performance. Sports Med. 2010;40(1):1-25.
Levine BD, Stray-Gundersen J. “Living high-training low”: effect of moderate-altitude acclimatization with low-altitude training on performance. J Appl Physiol. 1997;83(1):102-112.
Gore CJ, Parisotto R, Ashenden MJ, et al. Second-generation blood tests to detect erythropoietin abuse by athletes. Haematologica. 2003;88(3):333-344.
Sottas P-E, Robinson N, Giraud S, et al. Statistical Classification of Abnormal Blood Profiles in Athletes. The International Journal of Biostatistics [Internet]. 2006 [cited 28 Apr 2019]; 2. Available from: https://www.degruyter.com/view/j/ijb.2006.2.1/ijb.2006.2.1.1011/ijb.2006.2.1.1011.xml
Sottas P-E, Robinson N, Saugy M. The athlete's biological passport and indirect markers of blood doping. Handb Exp Pharmacol. 2010;195:305-326.
Dill DB, Horvath SM, Dahms TE, Parker RE, Lynch JR. Hemoconcentration at altitude. J Appl Physiol. 1969;27(4):514-518.
Lobigs LM, Sharpe K, Garvican-Lewis LA, et al. The athlete's hematological response to hypoxia: a meta-analysis on the influence of altitude exposure on key biomarkers of erythropoiesis. Am J Hematol. 2018;93(1):74-83.
Geistlinger, M, Koolaard, D. CAS 2016/O/4464 International Association of Athletics Federation (IAAF) v. All Russia Athletics Federation (ARAF) & Ekaterina Sharmina. 2016.
Bonne TC, Lundby C, Lundby AK, Sander M, Bejder J, Nordsborg NB. Altitude training causes haematological fluctuations with relevance for the athlete biological passport. Drug Test Anal. 2015;7(8):655-662.
Schumacher YO, Garvican LA, Christian R, et al. High altitude, prolonged exercise, and the athlete biological passport. Drug Test Anal. 2015;7(1):48-55.
Garvican-Lewis LA, Vuong VL, Govus AD, et al. Influence of combined iron supplementation and simulated hypoxia on the haematological module of the athlete biological passport. Drug Test Anal. 2018;10(4):731-741.
Sanchis-Gomar F, Pareja-Galeano H, Brioche T, Martinez-Bello V, Lippi G. Altitude exposure in sports: the athlete biological passport standpoint. Drug Test Anal. 2014;6(3):190-193.
Garvican-Lewis LA, Sharpe K, Gore CJ. Time for a new metric for hypoxic dose? J Appl Physiol. 2016;121(1):352-355.
Chapman RF, Karlsen T, Resaland GK, et al. Defining the “dose” of altitude training: how high to live for optimal sea level performance enhancement. J Appl Physiol. 2014;116(6):595-603.
WADA. The World Anti-Doping Code International Standard for Testing [Internet]. 2015 [cited 2018 Aug 9]. Available from: https://www.wada-ama.org/sites/default/files/resources/files/WADA-2015-ISTI-Final-EN.pdf
WADA. WADA Technical Document - TD2018BAR [Internet]. 2018 [cited 9 Aug 2018]. Available from: https://www.wada-ama.org/sites/default/files/resources/files/td2018bar_final_eng_1.pdf.
Robinson N, Kirchbichler A, Banuls O, et al. Validation of a blood stability score as an easy-to-use blood sample quality index. Int J Lab Hematol. 2016;38(6):685-693.
WADA. WADA Technical Document - TD2014EPO [Internet]. 2014 [cited 9 Aug 2018]. Available from: https://www.wada-ama.org/en/resources/science-medicine/td2014epo
Sottas P-E, Vernec A. Current implementation and future of the athlete biological passport. Bioanalysis. 2012;4(13):1645-1652.
Ashenden MJ, Hahn AG, Martin DT, Logan P, Parisotto R, Gore CJ. A comparison of the physiological response to simulated altitude exposure and r-HuEpo administration. J Sports Sci. 2001;19(11):831-837.
Parisotto R, Gore CJ, Emslie KR, et al. A novel method utilising markers of altered erythropoiesis for the detection of recombinant human erythropoietin abuse in athletes. Haematologica. 2000;85(6):564-572.
Damsgaard R, Munch T, Mørkeberg J, Mortensen SP, González-Alonso J. Effects of blood withdrawal and reinfusion on biomarkers of erythropoiesis in humans: implications for anti-doping strategies. Haematologica. 2006;91(7):1006-1008.
Martin L, Ashenden M, Bejder J, et al. New insights for identification of doping with recombinant human erythropoietin micro-doses after high hydration. Drug Test Anal. 2016;8(11-12):1119-1130.
Ashenden M, Gough CE, Garnham A, Gore CJ, Sharpe K. Current markers of the athlete blood passport do not flag microdose EPO doping. Eur J Appl Physiol. 2011;111(9):2307-2314.
Dehnes Y, Shalina A, Myrvold L. Detection of recombinant EPO in blood and urine samples with EPO WGA MAIIA, IEF and SAR-PAGE after microdose injections. Drug Test Anal. 2013;5(11-12):861-869.
Mairbäurl H. Neocytolysis: how to get rid of the extra erythrocytes formed by stress erythropoiesis upon descent from high altitude. Front Physiol. 2018;9(345):1-7.
Risso A, Ciana A, Achilli C, et al. Neocytolysis: none, one or many? A reappraisal and future perspectives. Front Physiol. 2014;5(54):1-10.
Robach P, Lafforgue E, Olsen NV, et al. Recovery of plasma volume after 1 week of exposure at 4,350 m. Pflugers Arch. 2002;444(6):821-828.
Schumacher YO, Saugy M, Pottgiesser T, Robinson N. Detection of EPO doping and blood doping: the haematological module of the athlete biological passport. Drug Test Anal. 2012;4(11):846-853.

Auteurs

Sven Christian Voss (SC)

Anti-Doping Laboratory Qatar, Doha, Qatar.

Khalifa Al-Hamad (K)

Anti-Doping Laboratory Qatar, Doha, Qatar.

Waseem Samsam (W)

Anti-Doping Laboratory Qatar, Doha, Qatar.

Anissa Cherif (A)

Anti-Doping Laboratory Qatar, Doha, Qatar.

Costas Georgakopoulos (C)

Anti-Doping Laboratory Qatar, Doha, Qatar.

Mohammed Al Maadheed (M)

Anti-Doping Laboratory Qatar, Doha, Qatar.

George Balanos (G)

School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Birmingham, Birmingham, UK.

Sam Lucas (S)

School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Birmingham, Birmingham, UK.

Pierre-Edouard Sottas (PE)

CoreMedica Campus Biotech Geneva, Switzerland.

Mathew Wilson (M)

Aspetar Orthopaedic and Sports Medicine Hospital, Research and Scientific Support, Doha, Ad Dawhah, Qatar.

Nathan Townsend (N)

Aspetar Orthopaedic and Sports Medicine Hospital, Research and Scientific Support, Doha, Ad Dawhah, Qatar.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH